The OIG has released another report comparing Medicare average sales prices (ASPs) for Part B drugs with average manufacturer prices (AMPs), this one summarizing data from 2009.  The OIG identified 34 drug Healthcare Common Procedure Coding System (HCPCS) codes with complete AMP data for which the ASP exceeded the AMP by at least 5% in one or more quarters of 2009.  If reimbursement for these codes had been lowered to 103% of the AMPs for the applicable quarters (as is authorized by the statute), Medicare spending would have been reduced by approximately $4.4 million from the third quarter of 2009 through the second quarter of 2010. The OIG excluded 10% to 12% of HCPCS codes from its comparisons because AMPs were missing or unavailable for all of the associated drug products. The OIG points out that while it has issued 20 reports comparing ASPs and AMPs, CMS has made no price adjustments to date as a result of the OIG’s findings.  CMS agreed with the OIG’s recommendation to take action against manufacturers that fail to submit timely drug pricing data. CMS did not concur, however, with recommendations to finalize a price substitution policy that lowers Medicare reimbursement amounts for drugs that exceed the 5% threshold or to seek legislation requiring all manufacturers of Part B-covered drugs to submit both ASPs and AMPs.